Targeted Antisense Oligonucleotides for UBE3A-ATS RNA Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurogenetic disorders like Angelman Syndrome are limited and often involve non-specific topoisomerase inhibitors that pose safety concerns due to DNA damage, while there is a lack of effective options for modulating UBE3A expression.
Innovation Solution
Development of compounds, particularly modified oligonucleotides, to reduce UBE3A-ATS RNA activity and increase paternal UBE3A RNA or protein expression, targeting specific symptoms such as developmental delays, ataxia, speech impairment, seizures, and EEG abnormalities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If topoisomerase inhibitors are used to unsilence paternal UBE3A expression, then paternal UBE3A expression is increased, but DNA damage occurs due to non-specific inhibition
Solution Approach 1:
The patent uses an antisense oligonucleotide as an intermediary molecule that specifically binds to UBE3A-ATS RNA transcript. This intermediary approach allows modulation of UBE3A-ATS without directly inhibiting topoisomerase enzymes, thereby achieving paternal UBE3A unsilencing while avoiding the DNA damage caused by non-specific topoisomerase inhibition.
Solution Approach 2:
The invention changes the molecular parameter from enzyme inhibition (topoisomerase) to RNA binding (antisense oligonucleotide). By altering the mechanism from small molecule enzyme inhibition to nucleic acid hybridization, the patent achieves specific targeting of UBE3A-ATS RNA while avoiding off-target effects on DNA topology enzymes.
2Quantity of substance
If non-specific topoisomerase inhibitors are used to treat Angelman Syndrome, then paternal UBE3A expression is increased, but safety concerns arise due to lack of specificity
Solution Approach 1:
The antisense oligonucleotide is designed with local specificity to bind only to the UBE3A-ATS RNA transcript at a defined target sequence. This localized binding ensures that only the intended molecular target is affected, providing high treatment safety while effectively increasing paternal UBE3A expression through specific molecular interaction rather than broad enzyme inhibition.
3Ease of operation
If conventional therapies are used for Angelman Syndrome, then symptomatic management is provided, but no effective disease-modifying treatment is available
Solution Approach 1:
The patent takes preliminary action by targeting the root molecular cause of Angelman Syndrome - the UBE3A-ATS antisense transcript that silences paternal UBE3A. By using antisense oligonucleotides to degrade or block UBE3A-ATS RNA before it can suppress paternal UBE3A expression, the treatment addresses the fundamental molecular defect rather than merely managing symptoms, enabling potential disease modification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively ameliorate symptoms of Angelman Syndrome by reducing UBE3A-ATS RNA activity and enhancing paternal UBE3A expression, providing a safer and more targeted therapeutic approach.
Implementation Method 1
The modified oligonucleotide is complementary to a sequence of the UBE3A-ATS RNA
Implementation Method 2
The internal region comprises 6-11 nucleosides that support RNase H cleavage
Data Source
AI summary
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A) in a cell or subject, and in certain instances increasing the expression of paternal UBE3A and the amount of UBE3A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurogenetic disorder. Such symptoms and hallmarks include developmental delays, ataxia, speech impairment, sleep problems, seizures, and EEG abnormalities. Such neurogenetic disorders include Angelman Syndrome.